Catalent has entered a strategic partnership with Galapagos to facilitate decentralised manufacturing in the US for the ...

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...

Specifically, Catalent's commercial cell therapy manufacturing facility in Princeton, New Jersey, will support manufacturing ...

After revenue boomed for biopharma manufacturers during the COVID pandemic, sales have stagnated for several CDMO giants, ...

Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, today announced a strategic collaboration with Galapagos NV (Euronext & NASDAQ: GLPG), a ...

Investment analysts at StockNews.com began coverage on shares of Catalent (NYSE:CTLT – Get Free Report) in a report released on Monday. The firm set a “hold” rating on the stock. Other equities ...

The deal advances Galapagos' plan to develop a decentralized CAR T-cell therapy for non-Hodgkin lymphoma with a one-week vein-to-vein time.

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 ...

For the fourth quarter, the Aristotle Small/Mid Cap Equity Composite generated a total return of -0.45% net of fees, ...

Novo Holdings plans to double its newly acquired contract drugmaker, Catalent, within five years, focusing on U.S. manufacturing. The $16.5 billion acquisition is aimed at enhancing supply chains amid ...

Will further expand Galapagos’ manufacturing network in the U.S. for improved patient experience.

Lennox International will join the S&P 500 before the open on Dec. 23, replacing Catalent, with the contract drug manufacturer acquired by Novo Nordisk. Lennox stock rose modestly late.